

(19) World Intellectual Property  
Organization  
International Bureau



PCT

16 FEB 2005



(43) International Publication Date  
4 March 2004 (04.03.2004)

(10) International Publication Number  
**WO 2004/017998 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 47/00**,  
9/107, 31/196

(21) International Application Number:  
PCT/EP2003/009302

(22) International Filing Date: 21 August 2003 (21.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02018772.0 22 August 2002 (22.08.2002) EP

(71) Applicant (for all designated States except US): **NOVARTIS CONSUMER HEALTH S.A.** [CH/CH]; Route de L'Etraz, CH-1260 Nyon (CH).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **STEIGER, Michel** [CH/CH]; Av. de la Perrausaz 90, CH-1814 La Tour-de-Peilz (CH).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
1 April 2004

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: TOPICAL EMULSION- GEL COMPOSITION COMPRISING DICLOFENAC SODIUM

(57) Abstract: The invention relates to beneficial topical pharmaceutical compositions comprising the diclofenac sodium salt in unusually low amounts. Said compositions represent opaque emulsion-gels, in which diclofenac is kept fully dissolved.

**BEST AVAILABLE COPY**